Status:
COMPLETED
Feasibility of a Novel Process-based Treatment for Patients With Psychosis
Lead Sponsor:
Max-Planck-Institute of Psychiatry
Conditions:
Schizophrenia
Schizotypal Disorder
Eligibility:
All Genders
18-70 years
Phase:
NA
Brief Summary
The purpose of this single-arm feasibility study is to develop and pilot test a novel process-based and modular group therapy approach for patients with acute psychotic symptoms in an inpatient settin...
Detailed Description
Due to the enormous economic and social costs of psychotic-spectrum disorders, increasing the effectiveness of treatment options has become an important subject for psychiatric research. Latest findin...
Eligibility Criteria
Inclusion
- Main diagnosis of a mental disorder with psychotic symptoms according to ICD-10 criteria currently experiencing delusions and hallucinations (F20, F21, F22, F23, F24, F25, F28, F29, F30.2, F31.2, F31.5, F32.3, F33.3) indicated by diagnostic assessment of attending MD
- Age between 18 and 70 years
- Informed consent to the study procedures and assessments (in written form)
Exclusion
- Severe neurological or internal concomitant diseases
- IQ \< 80; severe learning disability, brain damage or pervasive developmental disorder
- Missing eligibility for psychotherapy because of missing language skills/hostile or uncooperative behaviour.
- No further constraints will be imposed in order to collect data in a representative clinical sample.
Key Trial Info
Start Date :
May 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 23 2023
Estimated Enrollment :
37 Patients enrolled
Trial Details
Trial ID
NCT04874974
Start Date
May 10 2021
End Date
September 23 2023
Last Update
October 23 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Max Planck Institute of Psychiatry
Munich, Bavaria, Germany, 80804